SLAMF6 and Miyoshi myopathy: Lewis et al. evaluated the therapeutic effects of SGN-CD352A, a humanized anti-SLAMF6 antibody (h20F3ec) conjugated with a pyrrolobenzodiazepine (PBD) dimer, against MM [76].